SCHEDULE: Nantahala Capital Management Adjusts Stake in InhibiKinase

Nantahala Capital Management, LLC, along with Wilmot B. Harkey and Daniel Mack, has reported a beneficial ownership of 4.30% in InhibiKinase Therapeutics, Inc. as of June 30, 2026.

Summary

• Nantahala Capital Management, LLC, and its managing members Wilmot B. Harkey and Daniel Mack, have filed an amended Schedule 13G.
• As of June 30, 2026, the reporting persons collectively beneficially own 5,810,487 shares of InhibiKinase Therapeutics, Inc. common stock.
• This ownership represents 4.30% of the class of securities outstanding.
• The filing indicates that 3,108,624 of these shares may be acquired within sixty days through the exercise of convertible securities.
• The reporting persons are filing as investment advisers and control persons, asserting that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting a change in beneficial ownership percentage without new strategic or financial disclosures.

Positives

• The reporting persons hold a significant stake, indicating confidence or strategic interest in InhibiKinase Therapeutics.
• The potential to acquire additional shares through convertible securities suggests a forward-looking investment strategy.

Negatives

• The filing does not provide any new financial performance data or strategic updates for InhibiKinase Therapeutics, Inc.

Risks

• The reliance on convertible securities for a portion of the ownership introduces potential dilution risk if not managed effectively.
• The filing does not detail specific risks related to InhibiKinase Therapeutics' operations or market position.

Future Outlook

The filing does not contain forward-looking statements or guidance from InhibiKinase Therapeutics, Inc. The reporting persons' future outlook is implied by their potential acquisition of shares via convertible securities.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and indicate changes in significant shareholdings. This filing reflects ongoing investment activity within the biotechnology sector, where significant stakes are often taken by specialized investment firms.

Stakeholder Impact

• Shareholders may view the increased or maintained stake by Nantahala Capital Management as a positive signal of institutional interest, potentially influencing market perception.

Next Steps

• Continued monitoring of Nantahala Capital Management's stake in InhibiKinase Therapeutics, Inc.

Key Dates

Keywords

InhibiKinase Therapeutics, Schedule 13G, Beneficial Ownership, Nantahala Capital Management, Investment Adviser, Convertible Securities, Shareholder